Press Center

On September 8, 2026, the Ministry of Health and Family Welfare of India published a draft amendment to the Drugs Rules from 1945, according to which a pharmacy must dispense any prescription drugs under video surveillance that records the dispensing, and keep the recordings for at least three months. For companies operating in both markets, it is important to take into account the difference in approaches. We cover this in more detail in our legal alert.

The new review of the most notable patents disputes in Life Sciences in EAEU and CIS.

• pdf, 5.00 Mb

On 1 July 2026, amendments to Resolution of the Government of the Russian Federation No. 719 of 17 July 2015 “On the Certification of the Manufacture of Russian Industrial Products” (hereinafter “Resolution No. 719”) came into force.

We invite you to a webinar on antitrust risks for pharmaceutical companies when setting prices for medicinal products.

As part of the implementation of the Strategy for the Development of the Pharmaceutical Industry through 2030, approved by Decree of the Government of the Russian Federation No. 1495-r of 7 June 2023 (“Pharma Strategy 2030”), and discussions at the “Healthy Society” forum organized by the Roscongress Foundation with the support of the Ministry of Health (16–17 March 2026, Moscow) (“Forum”), key areas of state support for domestic drug developers and manufacturers were identified, including subsidies for clinical trials .

In addition to existing support programs, subsidies for clinical trials at all stages will help overcome the financing barrier for high-risk phases of medicines clinical trials and accelerate the market launch of medicines. The combination of current and planned measures will create the legal and economic foundation for strengthening the production and technological capacity of the domestic pharmaceutical industry and increasing its presence in international markets.

Below, we will examine planned initiatives and support measures for pharmaceutical manufacturers that have already been implemented.

On May 26, Moscow will host the XVII Antitrust Forum — the flagship event in Russian competition law. The forum is traditionally held with the support of the Federal Antimonopoly Service of Russia (FAS Russia) and the Association of Antimonopoly Experts (AAE). This year’s main theme is competition in the digital economy.

Lidings is an official partner of the forum and is organising a special session: “Pharmaceuticals & Antitrust: The Fight for Fair Competition Amid Economic Challenges.”

On April 24, 2026, the First All-Russian Conference of Young Specialists "LAW_EXPO" was held at St. Petersburg State University. The event brought together scholars, leading expert practitioners, and early-career researchers for a comprehensive analysis of key issues in information law.

Alina Smakova, an associate in the Data Protection & Technology practice at Lidings, took part in the conference.

The new review of the most notable patents disputes in Life Sciences in EAEU and CIS.

• pdf, 13.31 Mb

Lidings takes high positions in the new rating of the leading legal advisors in Russia based on the analytical research held annually by the “Kommersant” newspaper. In 2026 the firm is ranked among the TOP leading legal advisors in Russia.